Key Players
Competitive Landscape
The collagen market draws four supplier models: integrated gelatin producers, peptide specialists, formulation platforms and recombinant-collagen developers. Nutrition programs weigh source control and peptide evidence, whereas biomedical programs place heavier emphasis on material identity and clinical-grade supply.
Two 2025 agreements show where competitors began tightening control before the current expansion cycle. In June, CollPlant broadened its STEMCELL Technologies agreement from research use to clinical development and commercial-scale manufacturing. In December, Darling Ingredients and Tessenderlo Group signed a definitive agreement covering about 200,000 metric tons of combined collagen and gelatin capacity. Competition now turns on manufacturing control and disciplined application support instead of simple portfolio width.
Company developments mapped to drivers, trends and opportunities (2025-2026)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| BASF and Bota Biosciences launched a human-identical recombinant collagen III fragment in June 2026. | Personal-care formulators need collagen actives with defined human-sequence identity and industrial production evidence. | Recombinant collagen is entering commercial beauty formulations after years of laboratory development. | Facial-care developers gain a fermentation-derived collagen route for differentiated active systems. |
| Evonik launched clinical-grade VECOLLAN recombinant collagen in September 2025. | Medical-device developers need non-animal collagen grades that can enter clinical-study supply. | Recombinant collagen platforms are moving from laboratory programs into regulated clinical development. | Orthopedic and medical-aesthetic developers can qualify collagen-like biomaterials without animal-derived feedstocks. |
| Brenntag Nutrition signed an Asia-Pacific distribution agreement with Genu-in in July 2025. | Food and health manufacturers need regional access to traceable collagen peptides and gelatin. | Specialist distributors are broadening local collagen portfolios instead of relying on direct imports. | Regional formulation teams gain shorter commercial routes to collagen ingredients in six Asia-Pacific markets. |
Darling Ingredients, GELITA, Nitta Gelatin, Symrise, dsm-firmenich, PB Leiner, Lapi Gelatine and CollPlant cover manufacturing, formulation and recombinant-collagen positions beyond the three mapped actions.
Source: Future Market Insights, Collagen Market and Collagen Peptide Market Reports, 2026-2036.
The mapped companies collectively cover animal collagen, hydrolyzed peptides, gelatin, formulation support and recombinant collagen routes serving nutrition, beauty and biomedical programs.
Who leads the collagen market?
Darling Ingredients Inc., GELITA AG and Nitta Gelatin Inc. have the broadest documented manufacturing positions in gelatin and collagen peptides among the mapped companies.
Which suppliers have documented qualification or quality approvals?
Darling Ingredients documents third-party certification for selected peptide sourcing. Lapi Gelatine documents ASC certification for marine-source collagen and gelatin inputs.
Which companies provide collagen hydrolysate and peptide products?
Darling Ingredients Inc., GELITA AG, Nitta Gelatin Inc., PB Leiner and Lapi Gelatine S.p.A. provide hydrolyzed collagen or peptide formats for commercial applications.
Which suppliers serve North America and Europe?
Darling Ingredients Inc., GELITA AG, Nitta Gelatin Inc., Symrise AG, dsm-firmenich and CollPlant Biotechnologies Ltd. document commercial or development activity in both regions.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Darling Ingredients Inc. | Global gelatin and collagen peptide producer through Rousselot. | In June 2026, Rousselot received a USA patent covering Nextida GC collagen peptide composition and use. |
| GELITA AG | Global gelatin and collagen peptide manufacturer serving nutrition and biomedical applications. | In March 2026, GELITA signed a research and development agreement with Black Drop to develop gelatin-based bioinks. |
| Nitta Gelatin Inc. | Gelatin and collagen peptide producer with international manufacturing and application support. | In February 2025, Nitta Gelatin announced approved expansion of its Kerala gelatin production facilities with ramp-up scheduled that month. |
| Symrise AG | Health and beauty ingredient platform with a direct marine collagen partnership through Hofseth BioCare. | In March 2026, Symrise established its Care & Wellness Division covering cosmetic ingredients, health actives and biotics. |
| dsm-firmenich | Nutrition and beauty formulation platform with a direct collagen agreement through Jellice. | In October 2025, dsm-firmenich and Jellice signed an MOU for premium collagen formulations and Collameta distribution in Korea and Japan. |
| PB Leiner | Gelatin and collagen peptide manufacturer within Tessenderlo Group. | In June 2026, PB Leiner agreed to acquire the remaining minority stake in its Brazilian gelatin and collagen joint venture. |
| Lapi Gelatine S.p.A. | Italian gelatin and collagen producer with marine-source certification and Asian commercial expansion. | In January 2025, Lapi Gelatine renewed its ASC certification for responsibly sourced marine inputs used in gelatin and collagen production. |
| CollPlant Biotechnologies Ltd. | Recombinant human collagen developer serving regenerative medicine and bioink programs. | In February 2025, CollPlant received a USA patent covering a photocurable dermal filler based on modified recombinant human collagen. |
Research Methodology
The companies mapped here illustrate the market structure rather than an exhaustive ranking. Inclusion requires current, verifiable evidence that a company supplies collagen ingredients, collagen peptides, gelatin, recombinant collagen or collagen-focused formulation platforms within the defined market scope. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation and public filings. Capabilities are attributed to the stated collagen ingredient, peptide, gelatin, biomaterial or recombinant-collagen platform rather than generalised across broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
